A Practical Anaphylaxis Series: Recognize and Respond

Anaphylaxis is a life-threatening condition with a US incidence of 2.1 per 1,000 person-years and a lifetime prevalence of 1.6–5.1%. Most anaphylactic reactions occur outside the hospital setting, and the condition remains underdiagnosed and undertreated across all clinical environments.

Despite the availability of validated diagnostic criteria and clear guideline recommendations, significant gaps persist in recognition, acute management, discharge planning, long-term prevention, and awareness of emerging therapies. Barriers exist at the patient and systems level that may lead to suboptimal anaphylaxis management outcomes. This podcast addresses these gaps across two episodes.

This activity is provided by the American College of Allergy, Asthma & Immunology (ACAAI).

This activity is supported by an independent medical education grant from Aquestive Therapeutics.

Accreditation

Accreditation with Commendation - ACCMEThe American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
This activity will take up to 60 minutes to complete. To receive credit, learners are required to view the module(s), complete the evaluation, and pass the posttest.

Target Audience

This activity is intended for Allergists, Advanced Practice Providers, and office staff. 

Learning Objectives

Upon completion of this activity, learner will be better able to:

  • Describe the pathophysiology of anaphylaxis and how epinephrine imparts its physiologic effects.
  • Apply validated diagnostic criteria to recognize anaphylaxis, including age-specific and rapidly evolving clinical presentations.
  • Explain evidence-based management of anaphylaxis, including the rationale for first-line epinephrine use, barriers to timely treatment, and current U.S. and global epidemiologic trends.
Additional information
Disclosure: 

Disclaimer
The content of this activity was developed independently of any ineligible companies. The opinions expressed are those of the faculty and do not necessarily reflect the opinions of the ACAAI.

This activity was planned in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The educational content was reviewed for content validity to ensure that it is evidence-based, balanced, scientifically objective, and free of commercial bias.

Unapproved Uses of Drugs and Devices: This CME/CE activity may include discussion of investigational, off-label, or unapproved uses of drugs and/or devices. Please refer to the FDA-approved prescribing information for each drug or device for complete information regarding approved uses and prescribing recommendations.

Financial Disclosures
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, the ACAAI requires that all individuals in a position to control or influence the content of an activity disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.

All relevant financial relationships with ineligible companies have been reviewed and mitigated prior to this activity.

The following financial relationships have been provided:
David R. Stukus, MD, FACAAI
Sources of Funding for Research: DBV Technologies, ARS Pharmaceuticals
Consulting Agreements: Aquestive Therapeutics, Genentech

Jay A. Lieberman, MD, FACAAI
Consulting Agreements: Aquestive Therapeutics, ARS Pharmaceuticals
Independent Contractor: AbbVie, Amgen, Celldex Therapeutics, DBV Technologies
Advisor: Aquestive Therapeutics, DBV Technologies, Genentech, Kaleo Pharmaceutical

David B.K. Golden, MD, FACAAI
Consulting Agreements: ARS Pharmaceuticals, Blueprint Medicine, Genentech, Novartis, Thermo Fisher Scientific, Aquestive, Celldex, Kokua, Orexo
Speakers’ Bureau: ALK, ARS Pharmaceuticals

Syed Shahzad Mustafa, MD, FACAAI
Sources of Funding for Research: Takeda
Speakers’ Bureau: ARS Pharmaceuticals, AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi

ACAAI staff involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
11/10/2026
Course expires: 
11/09/2027
Rating: 
0

David R. Stukus, MD, FACAAI, Professor of Clinical Pediatrics, Division of Allergy and Immunology, Nationwide Children’s Hospital, Columbus, Ohio; Director, Food Allergy Treatment Center; President-Elect, American College of Allergy, Asthma & Immunology (ACAAI); Member, Joint Task Force on Practice Parameters; nationally recognized speaker and medical educator specializing in evidence-based allergy care, food allergy, and anaphylaxis.

Jay A. Lieberman, MD, FACAAI, Professor of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Program Director, Allergy & Immunology Fellowship Program; Department of Pediatrics, Division of Pediatric Pulmonology; physician, Le Bonheur Children’s Hospital; research interests include food allergy and anaphylaxis diagnosis; First-Year Regent, American College of Allergy, Asthma & Immunology (ACAAI).

David B.K. Golden, MD, FACAAI, Associate Professor of Medicine and Teaching Clinician, Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland; internationally recognized expert in anaphylaxis and insect sting allergy with more than 30 years of research experience; former Chief of the Allergy Division of Internal Medicine at Franklin Square Hospital and Sinai Hospital of Baltimore; active contributor to national and international allergy practice guidelines and medical education.

Syed Shahzad Mustafa, MD, FACAAI, Clinical Associate Professor of Medicine, University of Rochester, Rochester, New York; Chief of Allergy, Immunology, and Rheumatology, Rochester Regional Health; practices allergy and immunology in both pediatric and adult populations.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.